| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 23, 2013Presented at EuroPCR, One-Year Data from BELLO Study Show Durability of Clinical Results Following Treatment of De Novo Lesions with Novel Angioplasty Device
PARIS -- May 23, 2013 -- One-year data from an Italian multicenter randomized controlled trial of the IN.PACT Falcon drug-eluting balloon from Medtronic, Inc. (NYSE: MDT) demonstrate positive and...
-
May 23, 2013Replacing Degenerated Surgical Valves with CoreValve Results in Significant Hemodynamic Improvements for Patients
MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT) today announced it has received Conformité Européenne (CE) Mark for valve-in-valve (VIV) procedures using the CoreValve® and CoreValve®...
-
May 23, 2013Milestone Marks a Critical Step Forward in Bringing Renal Denervation to Patients in the U.S.
MINNEAPOLIS - May 23, 2013 - Medtronic, Inc. (NYSE: MDT), today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity(TM) renal...
-
May 21, 2013EuroPCR Presentation of "Real World" ADVANCE Study Confirms Economic Value of Novel Self-Expanding Valve in Patients Unable to Undergo Surgery
PARIS -- May 21, 2013 -- Focused on offering devices that provide both clinical and economic value, Medtronic, Inc. (NYSE: MDT) today unveiled the results of a cost-effectiveness model comparing...
-
May 21, 2013First Look at Data from Global SYMPLICITY Registry Shows Renal Denervation with the Symplicity(TM) System Meets Performance Expectations in Real-World Setting
MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT), announced today the first results from the Global SYMPLICITY Registry, which reaffirmed the safety of the renal denervation...
-
May 21, 2013Initial Results from Feasibility Study of the Symplicity Spyral(TM) Catheter Show Safety and Efficacy While More than Halving Mean Procedure Time
MINNEAPOLIS and PARIS - MAY 21, 2013 - Medtronic, Inc. (NYSE: MDT) announced today preliminary results from the feasibility study of its Symplicity SpyralTM multi-electrode, 6 Fr renal denervation...
-
May 21, 2013EuroPCR Presentation of One-Year Data from Robust "Real World" Global Study Demonstrates One of the Lowest Mortality Rates among Similar TAVI Studies
PARIS -- May 21, 2013 -- Committed to generating robust clinical data on its CoreValve System for transcatheter aortic valve implantation (TAVI), Medtronic, Inc. (NYSE: MDT) today unveiled for the...
-
May 21, 2013Q4 Revenue of $4.5 Billion Grew 5% at Constant Currency; 4% as Reported
MINNEAPOLIS - May 21, 2013 - Medtronic, Inc. (NYSE: MDT) today announced financial results for its fourth quarter and fiscal year 2013, which ended April 26, 2013. The Company reported worldwide...
-
May 21, 2013Proven Lead Expands Access to MRI for Patients with Slow Heartbeat
TOLOCHENAZ - May 21, 2013 -- Medtronic today announced CE Mark (Conformité Européenne) and launch of its CapSureFix Novus(TM)5076 Lead, which is now approved in the EU for use in an MRI...
-
May 21, 2013Three Analyses Presented at EuroPCR Demonstrate Device's Durability in Addressing Common Clinical Challenge
PARIS -- May 22, 2013 -- Addressing one of the most common clinical challenges in the treatment of complex coronary artery disease, three separate analyses on the program for EuroPCR this week...